AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7049112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 28634625 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on Mediterranean Diet (MD)
Number of subjects: 70
Study 28634625 — intervention group
Group type: COMPARATOR
Intervention: Updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention (Control)
Number of subjects: 70
Study 28634625 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups at the end of the study
Number of subjects: 70
Study 27027620 — intervention group
Group type: EXPERIMENTAL
Intervention: FineVision IOL
Number of subjects: 27
Study 27027620 — intervention group
Group type: COMPARATOR
Intervention: Tecnis ZMB00 IOL
Number of subjects: 27
Study 27027620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 27
Study 24550581 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan pretreatment (Group L)
Number of subjects: 50
Study 24550581 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment (Group C)
Number of subjects: 50
Study 22232535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound guided biopsy under antibiotic cover
Number of subjects: 1147
Study 20576462 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS intervention
Number of subjects: 28
Study 20576462 — intervention group
Group type: EXPERIMENTAL
Intervention: sham-SCS intervention
Number of subjects: 28
Study 20576462 — intervention group
Group type: COMPARATOR
Intervention: control intervention
Number of subjects: 28
Study 18186676 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage tract dilation with a 30F Amplatz dilator
Number of subjects: 100
Study 15891249 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% with doxycycline
Number of subjects: 0
Study 15891249 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 0
Study 12146769 — intervention group
Group type: EXPERIMENTAL
Intervention: Active brace
Number of subjects: 30
Study 12146769 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 30
Study 9469998 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (beractant) 100 mg/kg, four doses before ECMO and four additional doses during ECMO if required
Number of subjects: 328
Study 9469998 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 328
Study 7610735 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25-0.30 mg/kg BW)
Number of subjects: 50
Study 7610735 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (50 mg)
Number of subjects: 50
Study 1978613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with TOF nerve stimulation
Number of subjects: 80
Study 1978613 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium without TOF nerve stimulation
Number of subjects: 80
Study 1978613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium with TOF nerve stimulation
Number of subjects: 80
Study 1978613 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium without TOF nerve stimulation
Number of subjects: 80
Study 1978613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium and Pancuronium groups
Number of subjects: 80
Study 332488 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing amyloglucosidase and glucose oxidase
Number of subjects: 29
Study 332488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 31246976 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL functionality
Number of subjects: 506
Study 31246976 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL atherogenicity
Number of subjects: 506
Study 31246976 — intervention group
Group type: COMPARATOR
Intervention: Type-2 diabetes
Number of subjects: 506
Study 31246976 — intervention group
Group type: COMPARATOR
Intervention: Dyslipidemia
Number of subjects: 506
Study 31246976 — intervention group
Group type: COMPARATOR
Intervention: High body mass index
Number of subjects: 506
Study 31246976 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 506
Study 31246976 — intervention group
Group type: COMPARATOR
Intervention: Greater age
Number of subjects: 506
Study 28108992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of candida antigen, repeated every 3 weeks until complete improvement or for a maximum of three sessions.
Number of subjects: 60
Study 28108992 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen for a maximum of ten sessions or until clearance of all lesions.
Number of subjects: 60
Study 28108992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of candida antigen
Number of subjects: 60
Study 28108992 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 60
Study 28108992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional immunotherapy
Number of subjects: 60
Study 28108992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 25864134 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 57
Study 25864134 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving for marijuana
Number of subjects: 57
Study 25864134 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic self-efficacy
Number of subjects: 57
Study 25864134 — intervention group
Group type: EXPERIMENTAL
Intervention: Average minutes spent smoking marijuana
Number of subjects: 57
Study 23921339 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique
Number of subjects: 103
Study 23921339 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique
Number of subjects: 103
Study 20680245 — intervention group
Group type: EXPERIMENTAL
Intervention: Compaction by serial dilation (group SD)
Number of subjects: 40
Study 20680245 — intervention group
Group type: COMPARATOR
Intervention: Extraction drilling (group ED)
Number of subjects: 40
Study 19341921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined osteotomy (CO)
Number of subjects: 91
Study 19341921 — intervention group
Group type: COMPARATOR
Intervention: Closing-wedge osteotomy (CWO)
Number of subjects: 91
Study 17308968 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 0
Study 17308968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation with Zyoptix technique (Group A: flap lift with epitheliorhexis)
Number of subjects: 13
Study 15523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation with Zyoptix technique (Group B: microkeratome recut)
Number of subjects: 13
Study 11535769 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 18
Study 11535769 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 18
Study 9629992 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 23
Study 8768057 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg ethinyl estradiol (EE2) for 14 days followed by 0.04 mg EE2 and 0.125 mg levonorgestrel for 12 days
Number of subjects: 21
Study 8768057 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment over 26 days
Number of subjects: 21
Study 2148697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 0
Study 2148697 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 0
Study 2148697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin treatment and various schedules of warfarin prophylaxis
Number of subjects: 0
Study 2148697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin fractions or fragments
Number of subjects: 0
Study 2148697 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 7028242 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy with intravenous Poly I:C
Number of subjects: 32
Study 7028242 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without intravenous Poly I:C
Number of subjects: 32
Study 31918942 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR guidance
Number of subjects: 350
Study 31918942 — intervention group
Group type: COMPARATOR
Intervention: OCT imaging guidance
Number of subjects: 350
Study 31264114 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0
Study 31264114 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 28671095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of locking plate and anti-osteoporosis drug
Number of subjects: 120
Study 28671095 — intervention group
Group type: COMPARATOR
Intervention: Simple locking plate treatment
Number of subjects: 120
Study 25048788 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaledo board game intervention introduced weekly for 20 weeks
Number of subjects: 3110
Study 25048788 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaledo board game intervention
Number of subjects: 3110
Study 23897950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry sessions (6 sessions) followed by caregiver behavior training session delivered in-person by a local therapist.
Number of subjects: 223
Study 23897950 — intervention group
Group type: COMPARATOR
Intervention: Single telepsychiatry consultation (Control group).
Number of subjects: 223
Study 21227890 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS 0.4 mg kg(‐1) BID
Number of subjects: 451
Study 21227890 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS 0.3 mg kg(‐1) BID
Number of subjects: 451
Study 21227890 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS 0.2 mg kg(‐1) BID
Number of subjects: 451
Study 21227890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 19762041 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft (porcine grafts of small intestinal submucosa or dermal collagen)
Number of subjects: 50
Study 19762041 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene grafts (control group)
Number of subjects: 50
Study 19762041 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft
Number of subjects: 50
Study 19762041 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 50
Study 17566806 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ebastine daily (monotherapy)
Number of subjects: 4307
Study 17566806 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (not specified)
Number of subjects: 4307
Study 15020174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy alone or in combination with the Committed Quitters(R) program, and individual counseling (if applicable)
Number of subjects: 1869
Study 15020174 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment in addition to patch therapy
Number of subjects: 1869
Study 15020174 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoking cessation treatment offered in primary care settings
Number of subjects: 1869
Study 15020174 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority patients
Number of subjects: 1869
Study 11695932 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching SCGs about safe sleep practices (2 teaching sessions during the third trimester).
Number of subjects: 223
Study 11695932 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching SCGs about safe sleep practices.
Number of subjects: 223
Study 9161178 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Thermography (ET)
Number of subjects: 328
Study 1448398 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent large-scale investigations
Number of subjects: 0
Study 6736578 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial activation program
Number of subjects: 60
Study 6736578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 31504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary threonine (d-Thr) at 110% of NRC recommendation
Number of subjects: 900
Study 31504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary threonine (d-Thr) at 120% of NRC recommendation
Number of subjects: 900
Study 31504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM) diet
Number of subjects: 900
Study 31504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine supplementation (10%)
Number of subjects: 900
Study 31504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola meal (CM) diet
Number of subjects: 900
Study 29372191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 36
Study 29372191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 36
Study 29372191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP + fluoride
Number of subjects: 36
Study 29372191 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo paste)
Number of subjects: 36
Study 27068690 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health consultation focused on life coaching (111 patients)
Number of subjects: 218
Study 27068690 — intervention group
Group type: COMPARATOR
Intervention: No preventive consultation (107 patients)
Number of subjects: 218
Study 27068690 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who prioritized weight loss during consultation
Number of subjects: 218
Study 27068690 — intervention group
Group type: COMPARATOR
Intervention: Patients without prioritization of weight loss
Number of subjects: 218
Study 24789859 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4 as a first-line screen (Arm 1)
Number of subjects: 1172
Study 24789859 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4 as a second-line screen (Arm 2)
Number of subjects: 1172
Study 24789859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from both arms
Number of subjects: 1172
Study 24789859 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-indicated surgery
Number of subjects: 1172
Study 24789859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for surgical consultation
Number of subjects: 1172
Study 22252020 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 94
Study 22252020 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin
Number of subjects: 94
Study 22252020 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin
Number of subjects: 94
Study 22252020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 94
Study 20080264 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto Stentless Porcine Valve (SPV)
Number of subjects: 99
Study 20080264 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards pericardial valve (CE)
Number of subjects: 99
Study 16631177 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided self-instruction
Number of subjects: 92
Study 16631177 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face teaching
Number of subjects: 92
Study 16631177 — intervention group
Group type: COMPARATOR
Intervention: Combination of both methods
Number of subjects: 92
Study 16224050 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/daily)
Number of subjects: 0
Study 16224050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12171818 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 39
Study 12171818 — intervention group
Group type: COMPARATOR
Intervention: Heliox
Number of subjects: 39
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days with recombinant interferon-2b (IFN) at 3 MU/day for 7 days starting 2 days before chemotherapy administration.
Number of subjects: 204
Study 10091727 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) at 375 mg/m2 and levofolinic acid (1-FA) at 100 mg/m2 for 5 consecutive days without recombinant interferon-2b (IFN).
Number of subjects: 204
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and levofolinic acid (1-FA) with IFN.
Number of subjects: 204
Study 10091727 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and levofolinic acid (1-FA) without IFN.
Number of subjects: 204
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with limited liver involvement (regardless of chemotherapy arm).
Number of subjects: 204
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with massive liver involvement (regardless of chemotherapy arm).
Number of subjects: 204
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with limited liver disease.
Number of subjects: 204
Study 10091727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without liver involvement.
Number of subjects: 204
Study 7483775 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated immunization schedule (Group A)
Number of subjects: 912
Study 7483775 — intervention group
Group type: COMPARATOR
Intervention: Traditional immunization schedule (Group B)
Number of subjects: 912
Study 7483775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 912
Study 1685667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 13
Study 1685667 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol
Number of subjects: 13
Study 1685667 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers (Atenolol and Epanolol)
Number of subjects: 13
Study 1685667 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug treatment)
Number of subjects: 13
Study 7112697 — intervention group
Group type: EXPERIMENTAL
Intervention: disodium cromoglycate, hyposensitization with an aluminiumhydroxide‐adsorbed allergen extract of timothy, tall meadow oat and orchard grass, or combinations thereof
Number of subjects: 58
Study 7112697 — intervention group
Group type: EXPERIMENTAL
Intervention: disodium cromoglycate eye drops 2% and chlorpheniramine tablets 2 mg as supplementary treatment
Number of subjects: 58
Study 31066135 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring wrist-worn device
Number of subjects: 22
Study 31066135 — intervention group
Group type: COMPARATOR
Intervention: Self-directed workbook
Number of subjects: 22
Study 27879955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric levobupivacaine (HL group)
Number of subjects: 40
Study 27879955 — intervention group
Group type: COMPARATOR
Intervention: Isobaric levobupivacaine (IL group)
Number of subjects: 40
Study 27228641 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin emulsion
Number of subjects: 47
Study 27228641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 24345444 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (titrated to 10 mg twice daily)
Number of subjects: 94
Study 24345444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 24345444 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 94
Study 21924636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid, 10 mg/kg bolus before surgery followed by 1 mg/kg/h infusion during surgery
Number of subjects: 63
Study 21924636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 63
Study 19620954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg per feeding tube)
Number of subjects: 15
Study 19620954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17473078 — intervention group
Group type: EXPERIMENTAL
Intervention: Family and Medical Leave Act benefits
Number of subjects: 574
Study 17473078 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer-provided leave benefits (>4 weeks)
Number of subjects: 574
Study 17473078 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid leave benefits
Number of subjects: 574
Study 17473078 — intervention group
Group type: COMPARATOR
Intervention: No leave benefits
Number of subjects: 574
Study 15111672 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT1A receptor binding potential measured with PET and [Carbonyl-11C]WAY-100 635
Number of subjects: 14
Study 15111672 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 controls)
Number of subjects: 14
Study 11177010 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, 0.5 mg/kg
Number of subjects: 90
Study 11177010 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol, 20 microg/kg
Number of subjects: 90
Study 11177010 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide hydrochloride, 0.2 mg/kg
Number of subjects: 90
Study 9674679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Logic HP550 with regular brush head HP5924 (Philips, U.K.)
Number of subjects: 60
Study 9674679 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral B Plaque Remover (D7) with dedicated orthodontic brush head OD5‐1 (Braun AG, Germany)
Number of subjects: 60
Study 9674679 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dedicated orthodontic toothbrush (P35, Oral B Laboratories, Calif.)
Number of subjects: 60
Study 7913731 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120 vaccine (100 micrograms, 300 micrograms, or 600 micrograms)
Number of subjects: 57
Study 7913731 — intervention group
Group type: EXPERIMENTAL
Intervention: MN rgp120 vaccine (three doses)
Number of subjects: 57
Study 7913731 — intervention group
Group type: COMPARATOR
Intervention: Alum adjuvant alone (control)
Number of subjects: 57
Study 3422262 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis with 1,800 cGy cranial irradiation (CRT) plus intrathecal (IT) methotrexate (MTX)
Number of subjects: 40
Study 3422262 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX plus intravenous (IV) high-dose MTX (HDMTX)
Number of subjects: 40
Study 31190322 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 µg)
Number of subjects: 29
Study 31190322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg)
Number of subjects: 29